Avalyn Pharma Inc. 8-K

What Happened

• On May 1, 2026, Avalyn Pharma Inc. filed a Form 8-K (Item 5.03) disclosing that it filed an amended and restated certificate of incorporation with the Delaware Secretary of State and that amended and restated bylaws became effective in connection with the consummation of its initial public offering (IPO).
• The Board and stockholders previously approved these changes to be effective immediately prior to the closing of the IPO.

Key Details

• The Restated Certificate authorizes a total of 700,000,000 shares of common stock: 500,000,000 voting common shares and 200,000,000 non-voting common shares.
• The Restated Certificate removes references to the company’s prior series of preferred stock and authorizes 10,000,000 shares of undesignated preferred stock that the Board may issue in one or more series.
• The Amended and Restated Bylaws establish procedures for stockholder meetings, advance notice requirements for stockholder proposals and director nominations, and new nomination procedures, and they conform to the Restated Certificate.

Why It Matters

• These filings change Avalyn’s corporate charter and governance rules, which affect capital structure and how control and ownership rights are organized (notably explicit voting vs. non-voting common share classes).
• Authorizing a large number of common shares and up to 10 million preferred shares gives the company flexibility for future financings, equity grants, or other corporate actions that could dilute existing holders.
• The new bylaws’ advance-notice and nomination rules shape how and when shareholders can bring proposals or nominate directors, which matters for shareholder influence and governance.